Short Interest in AquaBounty Technologies, Inc. (NASDAQ:AQB) Declines By 26.6%

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 150,900 shares, a decline of 26.6% from the January 31st total of 205,500 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average daily volume of 480,600 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AquaBounty Technologies stock. Epiq Partners LLC boosted its position in AquaBounty Technologies, Inc. (NASDAQ:AQB) by 423.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 89,000 shares of the company’s stock after acquiring an additional 72,000 shares during the period. Epiq Partners LLC owned 2.30% of AquaBounty Technologies worth $56,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.92% of the company’s stock.

AquaBounty Technologies Price Performance

Shares of AQB traded up $0.01 during midday trading on Tuesday, reaching $0.67. The stock had a trading volume of 9,799 shares, compared to its average volume of 140,525. The company has a market capitalization of $2.60 million, a price-to-earnings ratio of -0.04 and a beta of 1.18. The company has a current ratio of 3.02, a quick ratio of 2.98 and a debt-to-equity ratio of 0.05. AquaBounty Technologies has a 12-month low of $0.47 and a 12-month high of $2.59. The company’s 50-day moving average is $0.75 and its 200 day moving average is $0.93.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.